Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-021-01754-0
Abstract: Despite increasing options for treatment of castration-resistant prostate cancer, development of drug resistance is inevitable. The glucocorticoid receptor (GR) is a prime suspect for acquired therapy resistance, as prostate cancer (PCa) cells are able to… read more here.
Keywords: therapy; androgen; anti androgen; prostate cancer ... See more keywords
Abstract 4791: Metabolic switch from glycolysis to oxidative phosphorylation (ox-phos) provides survival advantage to anti-androgen-treated prostate cancer cells and make them vulnerable to mitochondrial metabolism inhibitors IACS-010759 and CB-839
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-4791
Abstract: Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Background: Most cancer cells depend more on glycolysis for their energy need compared with their normal counterparts incubated under identical condition.… read more here.
Keywords: phos; glycolysis; switch; anti androgen ... See more keywords
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2023.12939
Abstract: Anti-androgen drugs are the standard pharmacological therapies for treatment of non-metastatic prostate cancer (PCa). However, the response of PCa cells may depend on the anti-androgen used and often patients become resistant to treatment. Thus, studying… read more here.
Keywords: anti androgen; lncap; prostate; expression ... See more keywords